Veloxis wins $1.3B buyout deal, and the new owner plans to follow up with new deals

Japan’s Asahi Kasei Pharma has stepped up with a deal to buy out Copenhagen-based Veloxis Pharmaceuticals for $1.3 billion, bagging an organ rejection drug in the process.